Abbvie Inc.

Abbott Laboratories Corporation

Bruce Clapham

Philip R Kym

Arthur Gomtsyan

Michael E Kort

Phil B Cox

Clara I Villamil

Michael J Dart

Jerome F Daanen

Erol K Bayburt

Robert G Schmidt

Eric A Voight

Chih-hung Lee

Anil Vasudevan

Michael R Schrimpf

Gregory A Gfesser

Kevin R Woller

Diana L Nersesian

Kathleen Mortell

Marlon D Cowart

Robert J Altenbach

John R Koenig

Huaqing Liu

David J Calderwood

Tammie K Jinkerson

Marc J Scanio

Mark A Matulenko

Michael Z Hoemann

Kathy A Sarris

Ryan G Keddy

Kerren Kalai Swinger

Noel S Wilson

Kelly Mullen

Gagandeep K Somal

Ana Aguirre

Philip Cox

Bin Li

Kathleen H Mortell

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, Z, Z, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Furo-3-carboxamide derivatives and methods of use

Disclosed herein are modulators of TRPV3 of formula (I) wherein G, X, X, X, X, X, G, Z, R, R, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G, X, X, X, X, X, G, Z, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are modulators of TRPV3 of formula (II): wherein G, X, X, X, X, X, G, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

[object Object]

The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

Amide derivatives as positive allosteric modulators and methods of use thereof

Growing community of inventors

Lindenhurst, IL, United States of America

Bruce Clapham